 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 2 | 1/1 | 返回列表 |
| 查看: 450 | 回復(fù): 1 | ||
[求助]
求助三段話翻譯
|
|
Local tolerance and sensitization studies External or histopathological evaluation of injection sites revealed no evidence of irritation in the singledose, repeated-dose or intermittent-dose studies. A tolerance study in rabbits used i.v. , paravenous p.v .; intradermal and intra-arterial (i.a.) administration of solutions of docetaxel in 0.9% aqueous NaCI containing polysorbate 80 at concentrations which were up to three times higher than those used in man; the results of this study indicated good tolerance by the i.a. and i.v. route and adequate tolerance by the p.v. route. Sensitization studies in mice, guinea pigs and rabbits revealed no evidence for sensitization, whereas a mild reaction was observed following intradermal re-challenge of docetaxel- pre-treated rabbits. In conclusion, the results of irritation and sensitization studies suggest a good tolerance and the absence of a signi白cant senslt1Za tion potential of the i. v. formulations of docetaxel Overall, the results of the preclinical toxicity studies indicate that the principal toxicological effects of docetaxel are compatible with the pharmacological (antimitotic) activity of the taxoid class of antineoplastic compounds.However,there were species-specific differences in the tolerance to the drug and in the susceptibility of principal target tissues. The results of the preclinical safety evaluations suggest that the monkey, in which hematopoietic effects (neutropenia) are the dose-limiting toxicity and in which i. v. administration of solutions containing polysorhate HO are well tolerated , may he the most suitahle large animal model for predicting the principal toxicities of docetaxel in man. The results of the acute toxicity study in dogs served as a hasis for the entry dose in man. Following recommendations of the :National Cancer Institute one third of the 'toxic dose low' in dogs (15mg/m2，i. e 5mg/m 2 ， was selected as the initial dose level for phase 1 clinical trials. |
回復(fù)此樓» 猜你喜歡
一志愿北京化工大學(xué)070300 學(xué)碩336求調(diào)劑
已經(jīng)有8人回復(fù)
-
一志愿東華大學(xué)化學(xué)070300，求調(diào)劑
已經(jīng)有6人回復(fù)
-
318求調(diào)劑
已經(jīng)有7人回復(fù)
-
求調(diào)劑一志愿海大，0703化學(xué)學(xué)碩304分，有大創(chuàng)項目，四級已過
已經(jīng)有6人回復(fù)
-
一志愿武理材料工程348求調(diào)劑
已經(jīng)有5人回復(fù)
-
求調(diào)劑
已經(jīng)有7人回復(fù)
-
275求調(diào)劑
已經(jīng)有6人回復(fù)
-
招08考數(shù)學(xué)
已經(jīng)有7人回復(fù)
-
303求調(diào)劑
已經(jīng)有6人回復(fù)
-
306求調(diào)劑
已經(jīng)有4人回復(fù)
2樓2014-09-17 16:24:57
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 小丸丸9 的主題更新
| 2 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 生物學(xué)一志愿985，分?jǐn)?shù)349求調(diào)劑 +4 | zxts12 2026-03-21 | 7/350 |
|
|---|---|---|---|---|
|
[考研] 085600材料與化工306 +4 | z1z2z3879 2026-03-21 | 4/200 |
|
|
|
[考研] 資源與環(huán)境 調(diào)劑申請(333分) +5 | holy J 2026-03-21 | 5/250 |
|
|
|
[考研] 333求調(diào)劑 +5 | 87639 2026-03-21 | 7/350 |
|
|
|
[考研] 工科0856求調(diào)劑 +3 | 沐析汀汀 2026-03-21 | 3/150 |
|
|
|
[考研] 307求調(diào)劑 +3 | 余意卿 2026-03-18 | 3/150 |
|
|
|
[考研] 306求調(diào)劑 +4 | chuanzhu川燭 2026-03-18 | 4/200 |
|
|
|
[考研] 初始318分求調(diào)劑（有工作經(jīng)驗） +3 | 1911236844 2026-03-17 | 3/150 |
|
|
|
[考研] 085700資源與環(huán)境308求調(diào)劑 +12 | 墨墨漠 2026-03-18 | 13/650 |
|
|
|
[考研] 311求調(diào)劑 +5 | 冬十三 2026-03-18 | 5/250 |
|
|
|
[考研] 085600材料與化工 +8 | 安全上岸！ 2026-03-16 | 8/400 |
|
|
|
[考研] 一志愿西南交通 專碩 材料355 本科雙非 求調(diào)劑 +5 | 西南交通專材355 2026-03-19 | 5/250 |
|
|
|
[考研] 0817 化學(xué)工程 299分求調(diào)劑 有科研經(jīng)歷 有二區(qū)文章 +22 | rare12345 2026-03-18 | 22/1100 |
|
|
|
[考研] 材料與化工專碩調(diào)劑 +7 | heming3743 2026-03-16 | 7/350 |
|
|
|
[考研] 08工學(xué)調(diào)劑 +5 | 用戶573181 2026-03-20 | 5/250 |
|
|
|
[考研] 085601材料工程專碩求調(diào)劑 +10 | 慕寒mio 2026-03-16 | 10/500 |
|
|
|
[考研] 308求調(diào)劑 +4 | 是Lupa啊 2026-03-16 | 4/200 |
|
|
|
[考研] 有沒有道鐵/土木的想調(diào)劑南林，給自己招師弟中～ +3 | TqlXswl 2026-03-16 | 7/350 |
|
|
|
[考研] 一志愿蘇州大學(xué)材料工程（085601）專碩有科研經(jīng)歷三項國獎兩個實用型專利一項省級立項 +6 | 大火山小火山 2026-03-16 | 8/400 |
|
|
|
[考研] 0856求調(diào)劑 +3 | 劉夢微 2026-03-15 | 3/150 |
|